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OBJECTIVES The objective was to determine the independent association between atrial fibrillation
(A-Fib) and activation of natriuretic peptides.
BACKGROUND The association of A-Fib with activation of N-terminal atrial and brain natriuretic peptides
(N-ANPs and BNPs, respectively) is uncertain but of great importance for the diagnostic
utilization of natriuretic peptides. This uncertainty is related to the lack of appropriate
controls, with left ventricular (LV) and atrial overload similar to A-Fib.
METHODS We prospectively measured N-terminal atrial and BNPs and endothelin-1 levels in 100
patients and 14 age- and gender-matched control subjects. The 32 patients with A-Fib were
compared with 68 patients in sinus rhythm and similar LV and atrial overload (due to mitral
regurgitation or LV dysfunction) measured simultaneously with hormonal levels with
comprehensive Doppler echocardiography.
RESULTS Patients with A-Fib compared with those in sinus rhythm had similar symptoms, comorbid
conditions, cardioactive medications, pulmonary pressure, left atrial volume, and LV ejection
fraction and filling characteristics but demonstrated higher N-ANP levels (2,613 6 1,681 vs.
1,654 6 1,323 pg/ml, p 5 0.007) even after adjustment for the underlying cardiac disease
(p , 0.0001). Conversely, BNP levels were similar in both groups (165 6 163 vs. 160 6 269
pg/ml, p 5 0.9). In multivariate analysis, a higher N-ANP level was associated with A-Fib
(p 5 0.0003), symptom class (p , 0.0001) and endothelin-1 level (p 5 0.032) independently
of left atrial volume and LV ejection fraction. Conversely, BNP showed no independent
association with and was most strongly associated with LV ejection fraction (p , 0.0001).
CONCLUSIONS Atrial fibrillation is an independent determinant of higher N-ANP levels and blurs its
association with LV dysfunction. Conversely, the BNP is not independently associated with
A-Fib and is strongly determined by LV dysfunction, for which it is an independent marker.
(J Am Coll Cardiol 2000;35:1256–62) © 2000 by the American College of Cardiology
The heart as an endocrine organ secretes natriuretic pep-
tides that allow homeostasis and control of the volume of
circulating blood (1). The levels of atrial and brain natri-
uretic peptides (ANPs and BNPs, respectively) are increased
in patients with congestive heart failure (CHF) (2,3),
especially in those with severe hemodynamic impairment
(1,4,5), and are strong predictors of prognosis in patients
with previous myocardial infarction (6) and CHF (7).
Because CHF is frequent (8) and associated with high
mortality (8,9), early treatment is essential, emphasizing the
need for early diagnosis before the occurrence of overt heart
failure (10). This, in turn, has raised the hope that the
hormonal activation associated with heart failure (10), in
particular that of natriuretic peptides, could be used for the
early diagnosis of left ventricular (LV) dysfunction (11).
N-terminal ANP (N-ANP), which has a prolonged half-life
(12), and BNP levels are increased in patients with LV
dysfunction (11,13–15), even if asymptomatic (11). How-
ever, the diagnostic use of these hormonal levels remains
controversial (16), in particular because other cardiac dis-
eases associated with aging (17) and atrial overload (18) may
also result in their activation.
Atrial fibrillation (A-Fib) is a frequent disease among the
elderly, who represent the same population affected by CHF
(19). Previous studies have suggested that C-terminal ANP
levels are elevated in patients with A-Fib (20,21). Regarding
N-ANP or BNP levels, specific information has been
limited or lacking (22,23), and A-Fib was either acute (23)
or associated mostly with concomitant left-sided heart
disease, such as cardiomyopathy or mitral stenosis
(22,24,25). Therefore, it is unclear whether chronic A-Fib
in and by itself, rather than left atrial (LA) enlargement
(18), hemodynamic impairment (23) or other hormonal
alteration, can result in elevation of N-ANP or BNP levels.
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An independent association would have major implications
for the utilization of hormonal levels in the diagnosis of LV
dysfunction and would raise important questions regarding
the significance of hormonal activation in A-Fib.
To analyze the intrinsic effect of A-Fib on natriuretic
peptides, it is essential to compare patients with A-Fib and
sinus rhythm with similar clinical characteristics and ranges
of atrial volume, hemodynamics and LV function. There-
fore, natriuretic peptide levels and comprehensive Doppler
echocardiography were obtained prospectively and simulta-
neously in patients with LA overload in sinus rhythm or
A-Fib to verify the hypothesis that A-Fib is a major
determinant of natriuretic peptide levels, independently of
LA volume, LV function or hemodynamic alterations.
METHODS
The patients were enrolled prospectively. Patient inclusion
criteria were 1) sinus rhythm with either primary (i.e., not
caused by valve or pericardial disease or acute myocardial
infarction) LV dysfunction (ejection fraction [EF] ,50%)
or organic mitral regurgitation (due to intrinsic valvular
disease) or 2) chronic A-Fib, idiopathic (lone) or due either
to primary LV dysfunction or to organic mitral regurgita-
tion. The duration of overt A-Fib ranged from six months
to 13 years (mean, 49 6 50 months). The underlying
cardiac disease was defined on the basis of history, clinical
examination and Doppler echocardiography. The method-
ologic inclusion criteria were 1) comprehensive quantitative
Doppler echocardiographic assessment and 2) simultaneous
venous blood sampling for measuring hormonal levels.
Exclusion criteria were as follows: 1) relatively recent onset
(,6 months) of A-Fib; 2) high heart rate (.120 beats/
min); 3) associated aortic valve disease, pericardial disease or
congenital heart disease as determined by Doppler echocar-
diography; and 4) known major comorbid condition such as
stroke or extensive atherosclerosis or renal, liver, or respira-
tory failure or malignancy. No exclusions were made on the
basis of gender, race, age, degree of mitral regurgitation or
degree of hemodynamic impairment. A total of 100 patients
were enrolled in the study. These patients were referred to
the echocardiographic laboratory for systolic murmur or
history of mitral regurgitation (n 5 58), for heart failure or
LV dysfunction (n 5 24) or for A-Fib (n 5 18). The mean
age was 70 6 8 years, and 37% were female. The symptoms
of heart failure (according to the New York Heart Associ-
ation [NYHA] class), the treatment received and associated
comorbid conditions were noted. Fourteen gender, and
age-matched subjects in sinus rhythm, with no history of
heart disease and entirely normal echocardiographic find-
ings referred to the echocardiographic laboratory to rule out
pericardial disease or for systolic murmurs, were enrolled as
a control group.
Echocardiographic study. All patients had a complete
two-dimensional echocardiographic and Doppler study that
used multiple windows, as previously described (26).
The quantitative Doppler study was performed as previ-
ously described (27,28), and mitral and aortic stroke vol-
umes were calculated. At least three measurements of each
variable were averaged (six in patients with A-Fib). Cardiac
output and index were calculated using the aortic stroke
volume (27). Both mitral and aortic stroke volumes were
used to calculate the mitral regurgitant volume and regur-
gitant fraction in all patients (28). In the presence of notable
mitral regurgitation, the regurgitant volume was also mea-
sured by the proximal isovelocity surface area method (29).
The measurement of regurgitant volume by these two
methods showed close correlation (r 5 0.98; p , 0.0001;
standard error of the estimate, 8.5 ml). In our laboratory
interobserver and intraobserver variabilities for regurgitant
volume are low, 3.9 6 4.8 and 6.0 6 3.8 ml, respectively.
Pulmonary artery systolic pressure was measured using the
tricuspid regurgitant jet velocity (30).
Left atrial volume was measured at end-systole (largest
atrial volume) with the use of two orthogonal apical views
(31). Right atrial volume was measured at end-systole with
a single plane method from the apical view. Left ventricular
filling was assessed by the E-velocity and deceleration time
obtained by pulsed-wave Doppler. Left ventricular end-
systolic and end-diastolic volumes were measured by using
the biapical Simpson’s rule, as recommended by the Amer-
ican Society of Echocardiography (32), allowing calculation
of the LV EF. The total LV stroke volume calculated by
this method and by the Doppler method showed close
correlation (r 5 0.98; p , 0.0001; standard error of the
estimate, 5.9 ml).
Blood sampling. At the end of the echocardiographic
examination and, thus, after the patient had been in a supine
position for at least 30 min, a blood sample was drawn from
a peripheral vein into edetic acid-coated tubes containing
chilled potassium, immediately placed on ice and centri-
fuged at 2,500 rpm at 4°C. Plasma was separated and stored
at 220°C. The N-ANP level was measured after extraction,
using a polyclonal antibody to human ANP 26–55. The
recovery is 86% and the intra-assay and interassay variabil-
ities are 6% and 9%, respectively. There is no cross-reactivity
with C-terminal ANP or BNP. The BNP level was mea-
sured using an assay with double antibody-coated beads to
Abbreviations and Acronyms
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ANOVA 5 analysis of variance
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
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N-ANP 5 N-terminal ANP
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human BNP. The intra-assay and interassay variabilities are
both 11%. The endothelin-1 level was measured after
extraction using a polyclonal rabbit antiendothelin-1 anti-
body. The recovery is 81% and intra-assay and interassay
variabilities 9% and 5%, respectively.
Statistical analysis. Results are presented as mean value 6
SD. The patients were divided into two groups according to
cardiac rhythm: sinus rhythm (group 1) and A-Fib (group
2). Differences were also tested between lone (primary) and
secondary (to mitral regurgitation or LV dysfunction)
A-Fib. Group comparisons were performed using a stan-
dard t test or chi-square test and comparison was also
stratified according to underlying cardiac disease using
analysis of variance (ANOVA). Linear and nonparametric
regression was used as appropriate with N-ANP and BNP
levels as the dependent variables and age, gender, presence
of A-Fib, NYHA class of symptoms, LV EF, LA and right
atrial volumes, cardiac index, systolic pulmonary artery
pressure and endothelin-1 measurements as independent
variables. Correlations were also analyzed separately in each
group. Multivariate analysis using stepwise multiple linear
regression was performed using the listed variables as
candidates to define the independent determinants of the
hormonal levels and was repeated with and without inclu-
sion of the control patients; p , 0.05 was considered
significant.
RESULTS
Baseline characteristics. Among the 100 patients, atrial
overload was due to organic mitral regurgitation in 58
(regurgitant volume 5 74 6 36 ml, LA volume 5 122 6 60
ml, 49 in sinus rhythm), to LV dysfunction in 24 (EF 5
33 6 8%, LA volume 5 112 6 61 ml, 19 in sinus rhythm)
and to lone A-Fib in 18 (EF 5 59 6 7%, LA volume 5
106 6 44 ml). By design, there was no difference in age
(p 5 0.6) and gender (percentage of women: 37% vs. 43%,
p 5 0.67) between patients and control subjects. As shown
in Table 1 (left part), in comparison to control subjects, the
patients showed signs of atrial overload, with significantly
higher LA and right atrial volumes, and altered hemody-
namics, with reduced cardiac index and higher pulmonary
pressure. The difference in LV EF was of borderline
significance. The atrial overload was due partly to the high
regurgitant volume (50 6 44 vs. 4 6 3 ml per beat, p ,
0.0001) and fraction (35 6 21% vs. 4 6 3%, p , 0.0001)
measured in patients, as compared with control subjects.
Accordingly, the hormonal measurements showed that
N-ANP and BNP levels in patients were significantly and
considerably higher than in control subjects. However, no
difference was observed for endothelin-1 levels.
A-Fib versus sinus rhythm. Patients with sinus rhythm
(group 1, n 5 68) compared with those with A-Fib (group
2, n 5 32) had a higher cardiac index and smaller right atrial
volume (Table 1) and were less often treated with digitalis
(p 5 0.005) or warfarin (p 5 0.004). However, no other
significant baseline difference was noted. There was no
difference in regurgitant volume between patients in sinus
rhythm or A-Fib, either in those with organic disease (i.e.,
mitral regurgitation or primary LV dysfunction) (61 6 41
vs. 55 6 52 ml per beat, p 5 0.66) or in those with lone
A-Fib compared with control subjects (6 6 4 vs. 4 6 3 ml
per beat, p 5 0.23). No difference was observed in LA
volume, LV EF and filling characteristics, systolic pulmo-
nary artery pressure or endothelin-1 level (Table 1). No
differences between the two groups were noted regarding
symptoms of heart failure (Table 1) or treatment with
angiotensin-converting enzyme inhibitors, calcium channel
blockers, beta-blockers, diuretics and antiarrhythmic drugs
(all p . 0.20) or comorbid conditions such as history of
hypertension (49% vs. 47%, p 5 0.88) or diabetes (16% vs.
Table 1. Comparison of the Baseline Characteristics of the Study Groups
Control
Group
(n 5 14)
Patients
(n 5 100)
p
Value
Sinus
Rhythm
(Group 1)
(n 5 68)
A-Fib
(Group 2)
(n 5 32)
p
Value
Age (yr) 69 6 8 70 6 8 0.6 70 6 7.6 72 6 7.2 0.18
NYHA $ II (%) 0 44 0.016 45 44 0.9
LV EF (%) 65 6 4.5 57 6 16 0.07 57 6 17 56 6 12 0.5
Cardiac index (L/min/m2) 3.1 6 0.5 2.7 6 0.6 0.03 2.8 6 0.7 2.5 6 0.5 0.03
Systolic PAP (mm Hg) 32 6 6 43 6 13 0.002 44 6 13 40 6 13 0.1
LA volume (ml) 55 6 14 117 6 58 0.0001 111 6 52 128 6 66 0.2
RA volume (ml) 47 6 9 70 6 34 0.0001 58 6 26 93 6 36 0.0001
E-velocity (cm/s) 69 6 15 94 6 28 0.0001 93 6 27 97 6 30 0.5
Deceleration time (ms) 247 6 40 192 6 47 0.0001 192 6 52 192 6 34 0.99
Endothelin-1 (pg/ml) 15.4 6 6.5 13.5 6 6.8 0.3 13.5 6 6.7 13.5 6 6.9 0.9
BNP (pg/ml) 29 6 42 161 6 239 0.0001 160 6 269 165 6 163 0.9
N-ANP (pg/ml) 910 6 536 1,961 6 1,507 0.01 1,654 6 1,323 2,613 6 1,681 0.007
A-Fib 5 atrial fibrillation; BNP 5 brain natriuretic peptide; EF 5 ejection fraction; LA 5 left atrial; LV 5 left ventricular; N-ANP 5 N-terminal atrial natriuretic peptide;
NYHA 5 New York Heart Association; PAP 5 pulmonary artery pressure; RA 5 right atrium.
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19%, p . 0.75). Nevertheless, comparison of hormonal
levels between groups showed that patients with A-Fib had
significantly higher N-ANP levels than those with sinus
rhythm (2,613 6 1,681 vs. 1,654 6 1,323 pg/ml; p 5
0.003) but no difference in BNP level (165 6 163 vs. 160 6
239 pg/ml; p 5 0.92). Comparison between patients with
A-Fib and sinus rhythm stratified according to underlying
heart disease (LV dysfunction, mitral regurgitation or nei-
ther) confirmed the significant differences for N-ANP
(adjusted p , 0.0001) and the lack of difference for BNP
(adjusted p 5 0.14).
Within group 2, patients with lone A-Fib (primary, n 5
18) in comparison to those with secondary A-Fib (with
organic disease, n 5 14) had a lower BNP level (106 6 94
vs. 240 6 202 pg/ml, p 5 0.035) but a similar N-ANP level
(2,339 6 1,542 vs. 2,968 6 1,841 pg/ml, p 5 0.30). There
was a trend, albeit not significant, toward a negative
association between duration of A-Fib and levels of N-ANP
(r 5 20.34, p 5 0.06) and BNP (p 5 0.20).
Determinants of natriuretic peptide levels. In the overall
population of patients and control subjects, the correlation
observed between LV EF and BNP (r 5 20.62, p ,
0.0001) was maintained in patients with A-Fib (r 5 20.51,
p , 0.003), whereas that with N-ANP was weak (r 5
20.22, p 5 0.017) and was observed only in those in sinus
rhythm (r 5 20.31, p 5 0.005) but not in A-Fib (r 5 0.04,
p 5 0.81). A significant correlation was also observed
between NYHA class of symptoms and N-ANP level (r 5
0.42, p , 0.0001) without interaction with the presence or
absence of A-Fib (p for interaction 5 0.36). Stratified by
symptom category, the N-ANP level was higher in patients
with A-Fib than in those with sinus rhythm (adjusted p in
ANOVA 5 0.0004, Fig. 1). Similarly, a significant corre-
lation was observed between NYHA class of symptoms and
BNP level (r 5 0.55, p , 0.0001) without interaction with
the presence or absence of A-Fib (p for interaction 5 0.20).
Stratified by symptom category, the BNP level was not
different between patients with A-Fib and those with sinus
rhythm (adjusted p in ANOVA 5 0.59, Fig. 2). No other
variable demonstrated correlations with N-ANP level with
r $ 0.40 in sinus rhythm or in A-Fib. Conversely, BNP
correlated significantly with systolic pulmonary artery pres-
sure (r 5 0.53, p , 0.0001) and LA volume (r 5 0.53, p ,
0.0001).
Of particular interest were variables with values different
between patients in A-Fib and those in sinus rhythm. Right
atrial volume and cardiac index showed poor correlations
with N-ANP (r 5 0.17, p 5 0.10 and r 5 20.30, p 5
0.002, respectively) and BNP (r 5 0.24, p 5 0.02 and r 5
20.36, p 5 0.0002, respectively). Also, digoxin treatment
was not associated with higher N-ANP or BNP levels
globally and within each group (all p . 0.05). Furthermore,
right atrial volume, cardiac index and digoxin treatment
were not independent predictors of N-ANP and BNP levels
in multivariate analysis.
The results of multivariate analysis are presented in Table
2. The independent determinants of higher N-ANP levels
were higher NYHA functional class, A-Fib and a higher
endothelin-1 level. This result was not altered if the control
subjects were removed from the model (p 5 0.0001, 0.0016
and 0.023, respectively). Conversely, the independent de-
terminants of higher BNP levels were lower LV EF and
higher LA volume, systolic pulmonary artery pressure and
endothelin-1 level. This result was not altered after removal
of the control subjects from the model (p 5 0.0001,
0.00001, 0.03 and 0.008, respectively).
DISCUSSION
The present study shows the following: 1) natriuretic
peptide levels are elevated in patients with LA overload; 2)
A-Fib is associated with markedly elevated N-ANP levels,
independently of symptoms, atrial volumes, LV function,
Figure 1. N-ANP levels in patients stratified by heart failure
functional class according to NYHA class I, II, and III or IV. In
each class, the left bar represents patients with sinus rhythm (SR)
and the right bar, patients with A-Fib. Bar height represents the
mean value; the mean 6 SD is indicated in each bar. The p values
are those noted in the two-way ANOVA.
Figure 2. BNP levels in patients stratified by heart failure func-
tional class according to NYHA class I, II, and III or IV. In each
class, the left bar represents patients in sinus rhythm (SR) and the
right bar, patients in A-Fib. Bar height represents the mean value;
the mean 6 SD is indicated in each bar. The p values are those
noted in the two-way ANOVA.
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and pulmonary pressure or endothelin-1 level; and 3) BNP
levels are not affected by the presence of A-Fib and are most
strongly and independently related to LV function. There-
fore, the clinical interpretation of natriuretic peptide levels
should be specific to the particular peptide examined but
also to the presence of A-Fib.
A-Fib and natriuretic peptides. Atrial fibrillation is a
frequent disease, particularly in the elderly (19). The prog-
nosis of A-Fib is linked to that of the causal disease, usually
benign in young patients with lone A-Fib (33), but more
often associated in the elderly with relatively high rates of
complications, including embolism and heart failure (19).
The progressive LA enlargement observed in patients with
A-Fib (34) may be partly responsible for these complica-
tions. These morphologic alterations also raise the question
that A-Fib may be associated with activation of natriuretic
peptides. Although the exact trigger for release of natriuretic
peptides is still debated, experimental and clinical studies
have suggested that atrial volume, pressure and wall stretch
are the main determinants of the activation of these peptides
and are all potentially altered in A-Fib (1,18,35–37).
Previous studies in small series of patients with A-Fib
reported increased levels of the short half-life peptide
C-terminal ANP, reflective of the instantaneous activation
of ANP (21,38). This activation was not consistently
observed (39) and may have been the result of associated
heart diseases (mitral stenosis, cardiomyopathy) or altered
hemodynamics (22,24,25,40). Little information is available
about the longer half-life peptide N-ANP (22,23) or BNP
levels (17), and no concomitant information on cardiac
function (particularly LA volume [34] and LV function
[22]) has been reported. Therefore, the respective role of
A-Fib or the underlying cardiac alterations in the potential
activation of natriuretic peptides is unclear.
To address these unresolved issues, the present study was
designed to compare patients with A-Fib to patients with
sinus rhythm with similar cardiac alterations, as determined
by an extensive Doppler-echocardiographic assessment.
Consequently, patients with sinus rhythm or A-Fib had very
similar baseline characteristics, in particular for LA volume,
EF and pulmonary pressure but also for symptoms, comor-
bid conditions and treatment. Using this population, we
observed that chronic A-Fib is independently associated
with higher N-ANP levels, which, therefore, are not con-
fined to acute A-Fib (23) or A-Fib associated with heart
failure (22). This univariate association was confirmed in
comparisons stratified to the causal cardiac disease and in
multivariate analysis adjusting for baseline determinants of
N-ANP, in particular, symptoms and EF. Conversely,
despite the association between BNP level and LA volume
observed in the present study, there was no independent
association of BNP level with A-Fib (17). These results
were confirmed after adjustment for the level of
endothelin-1, which may stimulate natriuretic peptide se-
cretion independently of hemodynamic alterations (41).
These results were also confirmed in lone A-Fib, which is
associated with less hemodynamic alteration than secondary
A-Fib. In lone A-Fib compared with secondary A-Fib, the
N-ANP levels were not significantly different, but the BNP
levels were significantly lower. These data confirm that
BNP secretion closely reflects hemodynamic alterations
(42), but also that any form of A-Fib even without heart
failure can lead to high N-ANP levels.
The mechanism of increased N-ANP levels in A-Fib is
unknown. Experimental and clinical studies have suggested
that in failing myocardium, ANP secretion increases be-
cause of the up-regulation of ANP gene expression linked to
the hypertrophic process (43–45). The hypothesis of an
intrinsic atrial myocardial failure associated with A-Fib is
consistent with our observation of no significant correlation
between the hemodynamic status and the N-ANP level in
patients with A-Fib and is supported by recent histologic
data suggesting that A-Fib presents as an isolated atrial
cardiomyopathy (46,47). The decrease of natriuretic pep-
tides observed after cardioversion (20,24,25) does not rule
out the possibility of intrinsic atrial myocardial alteration
and may reflect transient inhibition of ANP secretion, as
suggested by the trend for delayed recurrent increase in
ANP (20) and by the inhibition of secretion also observed
after the Maze procedure (48). Another possible link between
A-Fib and excess ANP secretion is through G-protein
alterations. As recently demonstrated, G-proteins, which
form the switchboard between a family of receptors and
intracellular effector molecules, mediate ANP secretion (49)
and ion channel regulation (50) and, thus, may influence
electrical stability of the myocyte membrane and have a role
in generating A-Fib.
Clinical implications. Clinically, the independent associ-
ation between A-Fib and N-ANP level raises the question
of the role of N-ANP level in prognostic stratification. In
CHF and ischemic heart disease, higher N-ANP levels are
associated with worse outcome (6,7). Although the N-ANP
level in A-Fib is not acutely predictive of return to sinus
rhythm (23), its large individual variation suggests a poten-
tial role as a prognostic indicator that should be evaluated in
large long-term studies.
Table 2. Determinants of Natriuretic Peptide Levels in
Multivariate Analysis
Variable N-ANP BNP
A-Fib 0.0003 —
NYHA class 0.0001 —
LV EF — 0.0001
LA volume — 0.0001
ET-1 0.032 0.016
Systolic PAP — 0.005
A-Fib 5 atrial fibrillation; BNP 5 brain natriuretic peptide; EF 5 ejection fraction;
ET-1 5 endothelin-1; LA 5 left atrial; LV 5 left ventricular; N-ANP 5 N-terminal
atrial natriuretic peptide; NYHA 5 New York Heart Association; PAP 5 pulmonary
artery pressure.
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Another important clinical issue is the use of natriuretic
peptides as diagnostic markers for LV dysfunction. Con-
gestive heart failure is the source of high morbidity and
mortality (9) and is due most often to LV dysfunction (10).
Recognizing LV dysfunction before overt failure is chal-
lenging but may allow early treatment (10). Previous studies
demonstrated that ANP levels are increased in patients with
CHF (3) proportionally to the degree of hemodynamic
alteration (2,5). Therefore, several studies have attempted to
define the role of natriuretic peptides as markers of LV
dysfunction, with or without symptoms (11,13–15). Al-
though all studies found significant diagnostic value of
natriuretic peptides as markers of LV dysfunction (11,13–
15), some inconsistencies were observed, suggesting that
either N-ANP (13) or BNP (14,15) had a superior diag-
nostic accuracy. These discrepancies suggest that the diag-
nostic value of natriuretic peptides for LV dysfunction is
dependent on the population in which it is applied. This is
particularly relevant in the elderly, in whom many interac-
tions are possible (17) and in whom both heart failure and
A-Fib are particularly frequent (19). Although our data
confirmed a correlation between N-ANP level and LV EF
(11), the observation that N-ANP is strongly influenced by
A-Fib (40) limits the value of this peptide as a marker of LV
dysfunction. This observation is consistent with the most
recent large cohort series, which observed a relatively low
specificity of N-ANP (14,15). Conversely, BNP is not
independently influenced by A-Fib and shows a strong
correlation with EF, even in this population with atrial
overload, which is a potential explanation for its high
sensitivity and specificity as a diagnostic marker for LV
dysfunction (14,15).
Study limitations. Analysis of the diagnostic value or of all
possible hemodynamic determinants of natriuretic peptides
would require very large sample sizes, which could not be
achieved in a prospective study concomitantly with extensive
Doppler echocardiographic assessment. However, these
were not the goals of the study, and appropriate adjustment
for major hemodynamic variables, comorbid conditions,
treatment and other hormonal alterations could be achieved
to analyze the independent effect of A-Fib on natriuretic
peptides (21). Left atrial overload was specifically analyzed
by measuring atrial volume, which reflects atrial remodeling
(34) better than the M-mode atrial size used in previous
studies (21). By using patients in sinus rhythm with atrial
overload for comparison, the bias of major differences in
cardiac status observed between patients with sinus rhythm
and those with A-Fib was avoided, and most baseline
characteristics were identical between the two groups, which
is a unique feature of the present study. Right atrial volume
was also measured and significant differences were observed
between patients with A-Fib and those in sinus rhythm, but
because of the wide range of values, these differences could
be adjusted for in multivariate analysis. Therefore, these
differences do not alter the conclusions of the study regard-
ing the associations of A-Fib with natriuretic peptides.
The control population was referred to the echocardiog-
raphy laboratory, and bias may be a concern. However, the
N-ANP levels were very similar to those obtained in
population-based studies (23) and the echocardiographic
measurements were similar to those defined by the Amer-
ican Society of Echocardiography (32), in agreement with
an appropriate control population.
Although the present study was not designed to address
the molecular mechanism of activation of ANP in patients
with A-Fib, it could analyze the relationship of natriuretic
peptide activation with hemodynamic alterations, atrial
overload and LV function. Future experimental and human
studies should explore these mechanistic issues as well as the
prognostic impact of this association.
CONCLUSIONS
Comparison of patients with A-Fib to patients with sinus
rhythm with similar clinical characteristics, LA overload,
LV EF and filling characteristics, pulmonary pressure and
endothelin-1 level showed that A-Fib is independently
associated with a higher N-ANP level and blurs the asso-
ciation of N-ANP with reduced LV function. Conversely,
the BNP level is not independently affected by A-Fib and
remains strongly associated with LV dysfunction, for which
it can be used as a marker both in sinus rhythm and A-Fib.
Reprint requests and correspondence: Dr. Maurice Enriquez-
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55905.
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